Effective November 15, 2018, the Board of Directors of Vitality Biopharma, Inc. increased the size of the Board from three (3) to five (5) directors and appointed Edward Feighan and Michael Cavanaugh as directors to fill the vacancies on the Board created by the increase in the size of the Board, each to serve until the next annual meeting of the Company’s stockholders and thereafter until his respective successor has been duly elected and qualified, or until his earlier resignation or removal. The Board has determined that both Mr. Feighan and Mr. Cavanaugh are “independent” as contemplated by governing laws and applicable regulations, including Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Mr. Cavanaugh was appointed to the Audit Committee, the Compensation Committee and the Nomination and Corporate Governance Committee of the Board. Mr. Feighan was appointed as Chairman of the Board, replacing Dr. Avtar Dhillon, and to the Compensation Committee and the Nomination and Corporate Governance Committee of the Board. In connection with the appointments of Mr. Cavanaugh and Mr. Feighan, Dr. Anthony Maida, an existing member of the Board, was also appointed as the Chairman of the Audit Committee of the Board. Mr. Feighan is currently the Chairman and CEO of Covius LLC, a privately-held firm providing a range of services to the mortgage securitization industry. Mr. Cavanaugh is currently the Chief Investment Officer of Tower 1, an investment firm focused on private and public investments in a variety of industries.